Furthermore, blockage of CD49f was tested as therapeutic approach identifying pranlukast, a drug used to treat asthma, as inhibitor of CD49f preventing adhesion of breast cancer cells to laminin, mammosphere formation and CD49f-dependent PI3K activation [46]. The gene discussed is LAMB2; the disease is asthma.